FOR INVESTORS

Investors & Media

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Ardelyx's financial performance into perspective.

NASDAQ: ARDX

$13.80

+ 0.80 (+6.15%)

4:00 PM ET on Feb 23, 2017

Delayed at least 20 minutes.

NEWS

Feb 17, 2017

Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results

FULL ARTICLE

Feb 15, 2017

Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease

FULL ARTICLE

EVENTS & PUBLICATIONS

Feb 15, 2017 at 8:30 AM ET

Ardelyx Clinical Update

READ MORE

Jan 10, 2017 at 3:30 PM PT

J.P. Morgan 35th Annual Healthcare Conference

READ MORE

Nov 7, 2016 at 4:05 PM ET

Ardelyx Third Quarter 2016 Earnings Call

READ MORE

RESOURCES